A Multicenter, 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Participants With Rheumatoid Arthritis

Inclusion Criteria:

1. Participants must meet criteria for rheumatoid arthritis as defined by 2010 American
College of Rheumatology (ACR)/European League Against Rheumatism (EULAR)
classification at screening.

2. Participants must have persistently active rheumatoid arthritis defined as DAS 28-ESR
> 3.2 at screening.

3. Participants must have been on a corticosteroid 12 weeks prior to screening, with a
stable dose of 5-10 mg prednisone (or prednisone equivalent) for 4 weeks prior to
screening.

4. Participants must have been on either a non-biologic or biologic treatment in the 12
weeks prior to screening.

Exclusion Criteria:

1. Participants cannot have used intra-articular steroids within 14 days of the screening
visit.

2. Participants cannot have any known contraindication to Acthar.

3. Participants cannot have Type 1 or Type 2 diabetes.